MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
We haven't written up this one. Quartz has the full story — the link below goes straight to it.